DCP
PRCT icon

Davern Capital Partners’s Procept Biorobotics PRCT Stock Holding History

Davern Capital Partners’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.5M Buy
464,920
+203,720
+78% +$5.1M 1.79% 14
2026
Q1 		$6.53M Buy
+261,200
New +$7.36M 1.79% 15

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Davern Capital Partners's PRCT Position: Q2 2026 in Review

Davern Capital Partners increased its Procept Biorobotics (PRCT) stake by 78% in Q2 2026, buying an estimated $5.1M and bringing the position to 464,920 shares worth $10.5M. The position accounts for 1.79% of the portfolio, ranked #14.

Davern Capital Partners first reported a position in PRCT in Q1 2026 and has held it in 2 quarters since. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • Davern Capital Partners held 464,920 shares of Procept Biorobotics worth $10.5M as of Q2 2026.
  • Davern Capital Partners bought 203,720 Procept Biorobotics shares in Q2 2026, an estimated $5.1M.
  • Procept Biorobotics made up 1.79% of Davern Capital Partners's portfolio in Q2 2026, its #14 holding.
  • Davern Capital Partners first reported a position in Procept Biorobotics in Q1 2026 and has held it in 2 quarters since.
  • 254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Davern Capital Partners's 13F filing for Q2 2026, filed 13 Aug 2026.